Return to Home

Aldeyra Therapeutics, Inc.

ALDX

Find Out if You Qualify for a Financial Reward by filling out the form below.

Lead Plaintiff Deadline:
September 29, 2023

Days Left:
-434

calendar

Aldeyra Therapeutics, Inc. Form












Securities Fraud News does not share your information with others. There is no cost or obligation for you to submit.

Allegations

The filed complaint alleges that defendants made false statements and/or concealed that: (i) the ADX-2191 new drug application ("NDA") did not include adequate and well-controlled investigations and thus failed to show substantial evidence of ADX-2191’s effectiveness; (ii) as a result, the FDA was unlikely to approve the ADX-2191 NDA in its current form; (iii) accordingly, the Company had overstated ADX-2191’s clinical and/or commercial prospects; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Eligibility

In order to be included in the lawsuit, you must have incurred a loss on shares of Aldeyra purchased or acquired during the class period listed above.

Lead Plaintiff Deadline

If you suffered a loss in Aldeyra during the relevant time frame, you have until September 29, 2023 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Find More Cases

Ticker Symbol Company Name Join Deadline
UPS United Parcel Service, Inc. December 09, 2024 Join
EW Edwards Lifesciences Corporation December 13, 2024 Join
TD The Toronto-Dominion Bank December 23, 2024 Join
WOLF Wolfspeed, Inc. January 17, 2025 Join